Program
risankizumab
Also written as “Risankizumab”, “risankizumab IV” and “risankizumab SC”.
Its studies are mostly in Psoriasis · Crohn Disease · Arthritis, Psoriatic · Colitis, Ulcerative · Arthritis, Juvenile, led by 3 companies.
Drug pageRisankizumab: every studyAll 77 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 6515 open or running | phase 4since May 28, 2021 | Apr 10, 2012 | Jan 2027phase 1 · NCT07466550 |
| Johnson & Johnsonits history only | 21 open or running | phase 3since Mar 23, 2026 | Oct 11, 2021 | Nov 15, 2028phase 3 · NCT07499232 |
| Boehringer Ingelheimits history only | 10 open or running | phase 2since Feb 3, 2014 | Feb 3, 2014 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AbbVie only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 45 earlier studies, Jul 30, 2015 to Sep 20, 2023.
- Jun 9, 2015Named risankizumabINNProposed as its International Nonproprietary Name in WHO's List 113 · before, BI 655066
- Sep 26, 2023Phase 3 study in Crohn DiseaseNCT06063967 · 289 enrolled · United States, Argentina, Brazil and more
- Oct 20, 2023Phase 3 study in Arthritis, JuvenileNCT06100744 · 40 planned · United States, Australia, Canada and more
- Mar 21, 20242 phase 4 studiesNCT06333860, NCT06346288
- Jun 28, 2024Phase 1 study in Healthy VolunteersNCT06487572 · 60 enrolled · United States
- Aug 8, 2024Phase 2 study in Crohn DiseaseNCT06548542 · 590 planned · United States, Austria, Belgium and more
- Aug 23, 2024Phase 1 study in Healthy VolunteersNCT06571266 · 231 enrolled · United States
- Mar 4, 2025Phase 2 study in Arthritis, PsoriaticNCT06865105 · 300 planned · United States, Canada, Czechia and more
- Mar 12, 2025Phase 3 study in Colitis, UlcerativeNCT06880744 · 573 enrolled · United States, Austria, Bulgaria and more
- Apr 4, 20252 phase 1 studiesNCT06937619, NCT06946524
- May 28, 2025Phase 1 study in Healthy VolunteersNCT07007091 · 260 enrolled · United States
- Jul 8, 2025Phase 3 study in Colitis, UlcerativeNCT07071519 · 120 planned · United States, Belgium, Brazil and more
- Mar 9, 2026Phase 1 study in Healthy VolunteerNCT07466550 · 60 planned · United States
- Jul 7, 2026Phase 2 study in Crohn DiseaseNCT07697456 · 2,000 planned · United States, Canada, Israel and more
- Nov 9, 2026Primary completion moved from 2027-12 to 2029-08Date moved laterphase 2 · +20 months · NCT06865105
Ahead
- Jan 2027Primary completion: phase 1 study in Healthy VolunteerNCT07466550
- Mar 2027Primary completion: phase 3 study in Crohn DiseaseNCT06063967
- Aug 2027Primary completion: phase 3 study in Colitis, UlcerativeNCT06880744
- Feb 2028Primary completion: phase 3 study in Crohn DiseaseNCT04524611
TargetBeta
“Interleukin-23 inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| guselkumabrule | Johnson & Johnson | phase 4 | 60 |
| mirikizumabrule | Eli Lilly | phase 4 | 36 |
Studies
The newest 60 of 65 AbbVie leads. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07697456Crohn Disease · United States, Canada, Israel and more | 2 | Recruiting | Oct 2031 | 2,000 |
| NCT07466550Healthy Volunteer · United States | 1 | Recruiting | Jan 2027 | 60 |
| NCT07071519Colitis, Ulcerative · United States, Belgium, Brazil and more | 3 | Recruiting | Jul 2034 | 120 |
| NCT07007091Healthy Volunteers · United States | 1 | Completed | Jan 15, 2026 | 260 |
| NCT06946524Healthy Volunteers · United States | 1 | Completed | Nov 25, 2025 | 59 |
| NCT06937619Healthy Volunteer · United States | 1 | Completed | Nov 10, 2025 | 263 |
| NCT06880744Colitis, Ulcerative · United States, Austria, Bulgaria and more | 3 | Active, not recruiting | Aug 2027 | 573 |
| NCT06865105Arthritis, Psoriatic · United States, Canada, Czechia and more | 2 | Recruiting | Aug 2029 | 300 |
| NCT06571266Healthy Volunteers · United States | 1 | Completed | Apr 16, 2025 | 231 |
| NCT06548542Crohn Disease · United States, Austria, Belgium and more | 2 | Recruiting | Jan 2030 | 590 |
| NCT06487572Healthy Volunteers · United States | 1 | Completed | Feb 7, 2025 | 60 |
| NCT06346288Inflammatory Bowel Diseases · United States, Israel | 4 | Completed | Feb 5, 2026 | 10 |
| NCT06333860Moderate Plaque Psoriasis · United States, Australia, Belgium and more | 4 | Completed | Mar 19, 2026 | 393 |
| NCT06100744Arthritis, Juvenile · United States, Australia, Canada and more | 3 | Recruiting | Sep 2026 | 40 |
| NCT06063967Crohn Disease · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Mar 2027 | 289 |
| NCT06054425Healthy Volunteers · United States | 1 | Completed | May 6, 2024 | 48 |
| NCT05995353Crohn Disease · United States, Belgium, Bulgaria and more | 3 | Recruiting | Apr 2029 | 110 |
| NCT05969223Psoriasis · United States | 4 | Completed | Jan 22, 2025 | 214 |
| NCT05567029Healthy Volunteers · United States | 1 | Completed | Apr 20, 2023 | 198 |
| NCT05305222Healthy Volunteers · United States | 1 | Completed | Jun 15, 2018 | 17 |
| NCT05283694Healthy Volunteers · United States | 1 | Completed | Jun 12, 2018 | 48 |
| NCT05283681Healthy Volunteers · United States | 1 | Completed | Nov 11, 2019 | 226 |
| NCT05274100Healthy Volunteers · United States | 1 | Completed | Jul 6, 2021 | 394 |
| NCT05274087Healthy Volunteers · United States | 1 | Completed | Apr 7, 2021 | 30 |
| NCT05268068Healthy Volunteers · China | 1 | Completed | Apr 26, 2020 | 30 |
| NCT04908475Psoriasis · United States, Canada, Germany and more | 4 | Completed | Apr 20, 2023 | 352 |
| NCT04862286Psoriasis · United States, Canada, Germany and more | 3 | Active, not recruiting | Apr 2028 | 132 |
| NCT04713592Psoriasis · United States, Canada, Puerto Rico and more | 3 | Completed | Apr 20, 2023 | 174 |
| NCT04524611Crohn Disease · United States, Argentina, Australia and more | 3 | Active, not recruiting | Feb 2028 | 527 |
| NCT04451720Psoriasis · Japan | 3 | Completed | Nov 21, 2022 | 119 |
| NCT04435600Psoriasis · United States, Canada, Germany and more | 3 | Completed | Feb 12, 2024 | 139 |
| NCT04254783Colitis, Ulcerative · United States, Germany, Israel | 1 | Completed | Oct 14, 2022 | 20 |
| NCT04102007Plaque Psoriasis · United States, Australia, Germany and more | 3 | Completed | Jan 17, 2022 | 244 |
| NCT03926169Hidradenitis Suppurativa · United States, Australia, Canada and more | 2 | Completed | Feb 2, 2021 | 243 |
| NCT03875508Psoriasis · United States | 3 | Completed | Apr 24, 2020 | 108 |
| NCT03875482Psoriasis · United States, Puerto Rico | 3 | Completed | Feb 20, 2020 | 157 |
| NCT03706040Dermatitis · United States, Australia, Canada and more | 2 | Completed | Oct 28, 2020 | 172 |
| NCT03675308Arthritis, Psoriatic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Oct 8, 2020 | 964 |
| NCT03671148Arthritis, Psoriatic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jun 22, 2020 | 444 |
| NCT03518047Psoriasis · Russian Federation | 3 | Completed | Feb 11, 2020 | 50 |
| NCT03478787Psoriasis · United States, Canada, France and more | 3 | Completed | Jul 8, 2020 | 327 |
| NCT03398148Colitis, Ulcerative · United States, Argentina, Austria and more | 3 | Completed | Nov 9, 2022 | 1,558 |
| NCT03398135Colitis, Ulcerative · United States, Argentina, Austria and more | 3 | Active, not recruiting | Sep 2028 | 1,242 |
| NCT03255382Psoriasis · Germany | 3 | Completed | Jul 6, 2018 | 120 |
| NCT03219437Psoriasis · Brazil | 3 | Completed | Nov 26, 2021 | 104 |
| NCT03105128Crohn Disease · United States, Argentina, Australia and more | 3 | Completed | Nov 9, 2020 | 931 |
| NCT03105102Crohn Disease · United States, Argentina, Australia and more | 3 | Active, not recruiting | Feb 2029 | 1,336 |
| NCT03104413Crohn Disease · United States, Argentina, Australia and more | 3 | Completed | Nov 30, 2020 | 618 |
| NCT03047395Psoriasis · United States, Australia, Austria and more | 3 | Completed | Nov 29, 2023 | 2,170 |
| NCT03022045Psoriasis · Japan | 3 | Completed | Sep 17, 2017 | 18 |
| NCT03000075Psoriasis | 2 | Completed | Sep 21, 2017 | 182 |
| NCT02986373Arthritis, Psoriatic | 2 | Completed | Jul 8, 2018 | 145 |
| NCT02772601Psoriasis · Germany | 1 | Completed | Jun 15, 2017 | 21 |
| NCT02719171Arthritis, Psoriatic | 2 | Completed | May 2017 | 185 |
| NCT02694523Psoriasis | 3 | Completed | Aug 2017 | 684 |
| NCT02684370Psoriasis | 3 | Completed | Dec 2016 | 560 |
| NCT02684357Psoriasis | 3 | Completed | Dec 2016 | 577 |
| NCT02672852Psoriasis | 3 | Completed | Aug 2, 2017 | 507 |
| NCT02596217Healthy · Japan, Korea, Republic of | 1 | Completed | Jun 2017 | 80 |
| NCT02513459Crohn Disease · United States, Belgium, Canada and more | 2 | Completed | Jun 19, 2019 | 65 |
How it is read
Names in the registry
- “Risankizumab”, 53 entries
- “risankizumab”, 17 entries
- “risankizumab IV”, 4 entries
- “risankizumab SC”, 4 entries
- “BI 655066”, 3 entries
Conditions, from the studies’ own filings
- Psoriasis, 25 studies
- Crohn Disease, 11 studies
- Arthritis, Psoriatic, 6 studies
- Colitis, Ulcerative, 5 studies
- Arthritis, Juvenile, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.